Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years

Next Previous
X
Search
Trial Profile

Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atovaquone/proguanil (Primary) ; Chloroquine (Primary) ; Doxycycline (Primary) ; Rabies vaccine
  • Indications Malaria
  • Focus Pharmacodynamics
  • Acronyms MALRAB

    • Most Recent Events

    • 02 Nov 2019 Results assessing reduction in rabies antibody geometric mean titer in the chloroquine versus control groups were published in the Journal of Infectious Diseases
    • 02 Apr 2019 Status changed from recruiting to completed.
    • 04 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top